Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been given a consensus recommendation of “Hold” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $8.8571.

A number of research firms have weighed in on REPL. Piper Sandler lowered Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a research note on Friday, April 10th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. RTW Investments LP boosted its position in shares of Replimune Group by 11.6% during the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after purchasing an additional 744,620 shares during the period. State Street Corp raised its position in Replimune Group by 26.3% in the fourth quarter. State Street Corp now owns 3,693,107 shares of the company’s stock valued at $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. lifted its stake in Replimune Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares in the last quarter. Balyasny Asset Management L.P. boosted its position in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Finally, Toronto Dominion Bank boosted its position in shares of Replimune Group by 62.5% during the fourth quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company’s stock worth $21,671,000 after buying an additional 857,475 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Trading activity has been unusually heavy, suggesting investors are repositioning ahead of the FDA’s upcoming advisory committee meeting. The current move appears more consistent with volatility and a potential rebound after the prior selloff than with a new fundamental catalyst.
• Negative Sentiment: FDA staff reviewers questioned whether Replimune’s RP1 therapy has demonstrated sufficient efficacy in advanced melanoma. The concerns have raised expectations that the agency could reject or delay approval, making the advisory committee meeting a major near-term risk for REPL. Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy
• Negative Sentiment: Multiple law firms—including Kirby McInerney, Glancy Prongay Wolke & Rotter, and Howard G. Smith—announced investigations into whether Replimune or its executives violated securities laws or made misleading disclosures. These announcements do not establish wrongdoing, but they add legal and reputational overhang and could potentially lead to shareholder claims. Kirby McInerney investigation announcement
• Negative Sentiment: The investigations follow the FDA briefing-document disclosure that prompted a major one-day decline in REPL shares, as investors reassessed the probability of RP1 approval and the value of Replimune’s pipeline. Replimune shares fall on negative FDA comments

Replimune Group Trading Up 1.1%

REPL opened at $5.41 on Thursday. The firm has a market capitalization of $454.12 million, a price-to-earnings ratio of -1.60 and a beta of 0.86. The company’s 50 day simple moving average is $9.35 and its two-hundred day simple moving average is $7.37. Replimune Group has a 1-year low of $1.50 and a 1-year high of $12.50. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Analysts expect that Replimune Group will post -2.44 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.